Articles related to DEPRESSION

Rejoyn represents a significant advancement in the treatment of major depressive disorder, requiring prescription use and integrating brain-training exercises developed by leading mental health experts.

Recent clinical case studies highlight that symptoms such as sudden changes in blood sugar levels and depressive episodes without clear psychological causes may be indicative of early-stage pancreatic cancer.

Explore the potential of Rejoyn™, a digital therapeutic now cleared by the FDA, which has shown to significantly reduce depressive symptoms in adults as an adjunct to traditional outpatient care, without any reported adverse events.

The study elucidates the substantial impact of exercise, particularly walking or jogging, yoga, and strength training, in alleviating depressive symptoms, advocating for their inclusion as principal treatments in depression care, reflecting a broadened approach to mental health management.

Johns Hopkins psychiatrists are spearheading a novel educational initiative, ADAP Jr. High, to address the critical gap in middle schoolers’ understanding of anxiety and depression, offering structured lessons and coping strategies to empower young students.

This study emphasizes the potential of MSK1 methylation levels and executive function as key indicators in predicting suicidal ideation among adolescents with major depressive disorder, providing a new dimension to our understanding of suicide risk factors in this age group.